Every 8-K that Keros Therapeutics, Inc. (KROS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KROS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KROS filings page.
Keros Therapeutics, Inc. (KROS) announced that its board of directors approved a new stock repurchase program for up to $5 million of its common stock, to be implemented after receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. under a license agreement for elritercept.
As of June 30, 2026, Keros reported $257.6 million in cash and cash equivalents. Based on current operating plans, and after giving effect to the $20 million milestone and the $5 million stock repurchase, Keros anticipates this cash balance will fund operating and capital expenditure requirements into the second half of 2028.
Keros Therapeutics provided an updated corporate presentation describing its strategy as a clinical-stage biopharmaceutical company focused on disorders linked to dysfunctional TGF-β superfamily signaling. Lead candidate rinvatercept (KER-065), a modified activin receptor type II ligand trap, is being developed for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).
The presentation reports generally favorable safety and pharmacodynamic data from a Phase 1 healthy volunteer trial and outlines an ongoing open-label Phase 2 basket trial in DMD (about 24 patients) with initial data expected in the first half of 2027. Preclinical data in DMD and ALS models suggest effects on muscle mass, bone, fat, inflammation and neuromuscular junction integrity. A second asset, elritercept (KER-050), is licensed globally (excluding certain Greater China territories) to Takeda, with a $200 million upfront payment, potential milestones of over $1.1 billion, and tiered royalties, alongside the ongoing Phase 3 RENEW trial in myelodysplastic syndromes.
Keros Therapeutics, Inc. reported that it has issued a press release with its financial results for the quarter ended June 30, 2026. The press release, dated August 3, 2026, is provided as Exhibit 99.1 and is incorporated by reference for those detailed figures and disclosures.
Keros Therapeutics, Inc. announced it will receive a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. under their license agreement for elritercept, triggered by dosing of the first patient in the Phase 3 ELRiSE MDS clinical trial.
Under the global license, effective January 16, 2025, Keros previously received a $200 million upfront cash payment, is eligible for additional development, commercial and sales milestones that could exceed $1.1 billion, and may earn tiered royalties on net sales. Keros expects to distribute 25% of the net cash proceeds from this milestone payment to stockholders after receipt.
Keros Therapeutics, Inc. disclosed that Chief Financial Officer Keith Regnante resigned, effective August 3, 2026, to pursue other opportunities. The Board appointed Corporate Controller and Vice President, Finance, Annita Tanini, age 55, as interim principal financial officer and principal accounting officer effective August 4, 2026, while a search for a new CFO is underway.
Under a new executive employment agreement, Ms. Tanini will receive an annual base salary of $302,300 and be eligible for an annual cash bonus targeted at 30% of base salary. If terminated without cause or she resigns for good reason, she may receive six months of base salary and up to six months of COBRA premium payments, subject to a release. Mr. Regnante will receive accrued salary and standard benefits under his existing employment agreement and is not entitled to additional severance beyond amounts required by law.
Keros Therapeutics has appointed Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026, as a Class III director with a term running through the 2029 annual stockholder meeting. She has no related-party ties to the company and joins as an independent non-employee director.
Dr. Prener will receive an initial stock option award with a grant date fair value of $150,000, capped at 0.075% of common shares outstanding, vesting quarterly over three years, plus an initial RSU award with the same value and cap vesting in 12 quarterly installments. Both awards fully vest upon a Change in Control.
On an ongoing basis, she will be eligible for annual option and RSU awards of $75,000 each, each capped at 0.0375% of shares outstanding, and will receive a $41,500 annual cash retainer. Keros also highlighted her extensive prior leadership roles at multiple biopharmaceutical companies and academic and advisory positions.
Keros Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. A quorum was present and stockholders voted on director elections, auditor ratification and an advisory say-on-pay resolution.
Stockholders elected Jean-Jacques Bienaimé and Charles Newton as directors to serve until the 2029 Annual Meeting and until their successors are duly elected and qualified. They also ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as described in the April 22, 2026 proxy statement.
Keros Therapeutics, Inc. announced that President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 at 4:00 p.m. Eastern time.
A live audio webcast and an archived replay for up to 90 days will be available through links on the Investors section of the Keros website. The company is described as a clinical-stage biopharmaceutical business focused on therapeutics targeting dysfunctional signaling of the transforming growth factor-beta family of proteins, with lead candidates rinvatercept and elritercept in development for serious neuromuscular and hematologic disorders.
Keros Therapeutics reported a net loss of $23.7 million for the quarter ended March 31, 2026, compared with net income of $148.5 million a year earlier. The swing mainly reflects the absence of large license revenue recognized in 2025 from its agreement with Takeda and lower research and development activity.
Revenue fell to $0.4 million from $211.2 million, while research and development expenses declined to $16.1 million from $48.7 million as elritercept costs shifted to Takeda and a 2025 corporate restructuring reduced spending. General and administrative expenses were stable at $10.1 million. Keros ended the quarter with cash and cash equivalents of $281.5 million and expects this to fund operations into the first half of 2028, while its partner Takeda plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.
Keros Therapeutics filed an 8-K describing new clinical steps for its lead drug candidate, rinvatercept. The company has entered into an agreement with Massachusetts General Hospital to design a Phase 2 trial of rinvatercept in amyotrophic lateral sclerosis within the biomarker-driven Healey ALS MyMatch program.
Keros also reported presenting additional data from a Phase 1 trial of rinvatercept in healthy volunteers. Rinvatercept was generally well tolerated and produced changes in body composition, including increased muscle mass, reduced fat mass and higher bone mineral density, along with proteomic evidence of target engagement and effects on fibrosis, inflammation and energy metabolism.
The company highlighted preclinical mouse data in Duchenne muscular dystrophy and ALS models, and reiterated plans to advance rinvatercept into two Phase 2 clinical trials, one in Duchenne muscular dystrophy and one in ALS.
Keros Therapeutics furnished an updated corporate presentation outlining its pipeline and a major partnership for elritercept. The company highlights rinvatercept (KER-065), a TGF-β ligand trap in Phase 2 planning for Duchenne muscular dystrophy, with additional plans to engage regulators on a Phase 2 trial in amyotrophic lateral sclerosis in the second half of 2026.
The deck also details elritercept (KER-050), licensed globally (excluding mainland China, Hong Kong and Macau) to Takeda. Keros received a $200 million upfront payment and is eligible for over $1.1 billion in development, approval and commercial milestones, plus tiered royalties from low double-digits to high teens. A global Phase 3 RENEW trial in lower-risk myelodysplastic syndromes is underway, with transfusion independence as the primary endpoint.
Keros Therapeutics reported a strong turnaround in 2025, moving to net income of $87.0 million from a net loss of $187.4 million in 2024. Total 2025 revenue rose to $244.1 million, driven largely by license revenue from its agreement with Takeda. Research and development expenses fell to $129.6 million as Takeda assumed elritercept-related costs, while general and administrative expenses increased modestly to $46.8 million. Keros ended 2025 with $287.4 million in cash and cash equivalents and expects this to fund operations into the first half of 2028. The company is advancing rinvatercept into a Phase 2 trial in Duchenne muscular dystrophy and planning Phase 2 trial design discussions for amyotrophic lateral sclerosis in 2026.
Keros Therapeutics, Inc. appointed Charles Newton to its Board of Directors as a Class III director, effective March 9, 2026, with his term expiring at the 2026 annual meeting of stockholders. He will also serve on the Compensation and Audit Committees.
Newton will receive the company’s standard non-employee director compensation, including an initial stock option grant and an initial restricted stock unit award, each with a grant date fair value of $150,000, plus ongoing annual equity awards with grant date fair values of $75,000 each. He will also receive annual cash retainers totaling $57,000 for his Board and committee service and will enter into Keros’ standard indemnification agreement.
Carl Gordon, Ph.D., CFA, notified the Board of his resignation, effective March 9, 2026. The company states his resignation is not due to any disagreement regarding its operations, policies or practices. Keros concurrently updated the composition of its Audit, Compensation and Nominating and Corporate Governance Committees.
Keros Therapeutics, Inc. announced that President and CEO Jasbir S. Seehra will present at three upcoming healthcare investor conferences. He is scheduled for a corporate presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026, all in Eastern time. Webcast links are provided, and replays will be available in the Investors section of Keros’ website for up to 90 days after each event. Keros is a clinical-stage biopharmaceutical company developing protein therapeutics targeting dysfunctional signaling of the TGF-ß family of proteins, with lead candidates rinvatercept (KER-065) for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, and elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Keros Therapeutics, Inc. furnished an updated corporate presentation for use in meetings with investors, analysts and others. The company made this updated presentation available on its website and also attached it as Exhibit 99.1 to this current report. The presentation is dated January 2026 and is meant to provide additional background on the business.
The company states that the information in this report, including Exhibit 99.1, is being furnished under Regulation FD and is not considered filed for purposes of certain liability provisions of the Securities Exchange Act. It will only be incorporated into other securities filings if specifically referenced there.
Keros Therapeutics (KROS) furnished an Item 2.02 report stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference. The company notes the information is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor otherwise subject to that section’s liabilities. Securities listed include common stock on Nasdaq under KROS and preferred share purchase rights.
Keros Therapeutics entered agreements to repurchase all shares held by ADAR1 Capital Management and Pontifax Venture Capital, totaling 10,176,595 shares of common stock at $17.75 per share, for an aggregate purchase price of approximately $181 million. The company expects to complete these repurchases on or about October 15, 2025 and then intends to commence a tender offer to all holders at $17.75 per share to complete its previously announced plan to return $375.0 million to stockholders, subject to market conditions.
As of September 30, 2025, cash and cash equivalents are expected to be approximately $693.5 million (preliminary and unaudited). The ADAR1 parties beneficially owned 5,389,264 shares (about 13.3%) and the Pontifax parties 4,787,331 shares (about 11.8%) as of October 14, 2025. In connection with the Pontifax agreement, Tomer Kariv and Ran Nussbaum resigned from the board, and Jean‑Jacques Bienaimé was appointed Chair of the Nominating and Corporate Governance Committee. The repurchase parties agreed to standstill and voting commitments through the final certification of the 2028 annual meeting results, along with mutual non‑disparagement.
Keros Therapeutics, Inc. reported that it issued a press release on September 8, 2025 describing additional clinical data from its Phase 1 trial of KER-065 in healthy male volunteers. The company presented these data at the American Society of Bone and Mineral Research 2025 Annual Meeting held on September 6, 2025.
The Form 8-K notes that the press release is furnished as Exhibit 99.1 and is incorporated by reference, except for the quoted statements. No financial results or transaction details are included in this report, which focuses on the disclosure of new early-stage clinical information about KER-065.
Keros Therapeutics, Inc. filed a current report to share that its President and Chief Executive Officer, Jasbir Seehra, will speak at two upcoming investor conferences. On September 4, 2025, he is scheduled for a fireside chat at the 2025 Wells Fargo Healthcare Conference at 2:15 p.m. Eastern time. On September 9, 2025, he will give a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference at 12:00 p.m. Eastern time.
The company disclosed this through a press release dated August 28, 2025, which is furnished as Exhibit 99.1. The information under this item is being treated as “furnished” rather than “filed” under the Exchange Act, which limits its use for certain legal liability purposes and incorporation into other securities filings unless specifically referenced.
Keros Therapeutics reported that the U.S. Food and Drug Administration granted Orphan Drug designation to its investigational therapy KER-065 for treating Duchenne muscular dystrophy. This special status is reserved for drugs targeting rare, serious conditions and can provide regulatory and economic incentives to support development. The company disclosed this update through a press release, which is attached as an exhibit and incorporated by reference.